Evommune, Inc. (EVMN) compared with its closest peers (SPRY, OVID, SGMT, NBP, PRLD). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | $546.17M | -6.7 |
| Ovid Therapeutics Inc. (OVID) | $545.86M | — |
| Sagimet Biosciences Inc. (SGMT) | $544.42M | -3.7 |
| NovaBridge Biosciences (NBP) | $530.76M | -18.9 |
| Prelude Therapeutics Incorporated (PRLD) | $528.30M | -2.2 |
| MapLight Therapeutics, Inc. (MPLT) | $523.89M | -0.9 |
| XOMA Royalty Corp. (XOMA) | $505.65M | 16.8 |
| Rezolute, Inc. (RZLT) | $490.13M | -4.5 |
| Relmada Therapeutics, Inc. (RLMD) | $487.74M | -3.3 |
| Puma Biotechnology, Inc. (PBYI) | $476.97M | 17.9 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
EVMN overview · EVMN earnings · EVMN financials · EVMN KPIs · EVMN investor relations · EVMN ownership · EVMN filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.